<DOC>
	<DOCNO>NCT01842009</DOCNO>
	<brief_summary>The purpose study investigate mean number stimulation ( high definition-transcranial direct current stimulation ) session ( 26 ) need achieve clinical response response define 50 % decrease Visual Analog Scale ( VAS ) pain . These data important define optimal number session future fibromyalgia subject Phase III trial .</brief_summary>
	<brief_title>Single-arm , Open-label , Phase II Trial HD-tDCS Fibromyalgia Patients</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Providing informed consent participate study 18 85 year old , male female Have diagnosis Fibromyalgia Existing pain 3 month average least 4 010 VAS scale Pain resistant common analgesic medication chronic pain Tylenol , Aspirin , Ibuprofen , Soma , Parafon Forte DCS , Zanaflex Codeine . Pregnancy Contraindications tDCS : metal head implant brain medical device History alcohol drug abuse within past 6 month selfreported Use carbamazepine within past 6 month selfreported Severe depression ( score &gt; 30 Beck Depression Inventory ) Any history epilepsy , stroke , moderatetosevere traumatic brain injury severe migraine History unexplained faint spell selfreported Neurosurgery selfreported</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>transcranial stimulation</keyword>
	<keyword>direct current</keyword>
</DOC>